272 related articles for article (PubMed ID: 27633385)
21. Primary osteosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 22 cases with a review of the literature.
Gadwal SR; Gannon FH; Fanburg-Smith JC; Becoskie EM; Thompson LD
Cancer; 2001 Feb; 91(3):598-605. PubMed ID: 11169944
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
[TBL] [Abstract][Full Text] [Related]
23. Strategies for the targeted delivery of therapeutics for osteosarcoma.
Hughes DP
Expert Opin Drug Deliv; 2009 Dec; 6(12):1311-21. PubMed ID: 19761419
[TBL] [Abstract][Full Text] [Related]
24. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.
Salzer-Kuntschik M; Delling G; Beron G; Sigmund R
J Cancer Res Clin Oncol; 1983; 106 Suppl():21-4. PubMed ID: 6577010
[TBL] [Abstract][Full Text] [Related]
25. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
Cascini C; Chiodoni C
Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
[TBL] [Abstract][Full Text] [Related]
26. [Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].
Gomez-Brouchet A; Bouvier C; Decouvelaere AV; Larousserie F; Aubert S; Leroy X; Guinebretière JM; Coulomb A; Cassagnau E; de Muret A; Audard V; Marie B; de Pinieux G
Ann Pathol; 2011 Dec; 31(6):455-65. PubMed ID: 22172118
[TBL] [Abstract][Full Text] [Related]
27. Advances in differentiation therapy for osteosarcoma.
Chen Y; Cao J; Zhang N; Yang B; He Q; Shao X; Ying M
Drug Discov Today; 2020 Mar; 25(3):497-504. PubMed ID: 31499188
[TBL] [Abstract][Full Text] [Related]
28. Pathology of primary malignant bone and cartilage tumours.
Rozeman LB; Cleton-Jansen AM; Hogendoorn PC
Int Orthop; 2006 Dec; 30(6):437-44. PubMed ID: 16944143
[TBL] [Abstract][Full Text] [Related]
29. Structure-based Virtual Screening for the Identification of High-affinity Small Molecule Towards STAT3 for the Clinical Treatment of Osteosarcoma.
Khandelwal R; Chauhan APS; Bilawat S; Gandhe A; Hussain T; Hood EA; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(29):2511-2526. PubMed ID: 30430945
[TBL] [Abstract][Full Text] [Related]
30. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?
Yamamoto N; Tsuchiya H
Expert Opin Pharmacother; 2013 Nov; 14(16):2183-93. PubMed ID: 23919484
[TBL] [Abstract][Full Text] [Related]
32. [Osteogenic osteosarcoma and drug therapy. Study in vitro of osteosarcoma's sensitivity to drugs. Therapeutic applications].
Morasca L; Roy-Camille R; Pouliquen JC
Chirurgie; 1970; 96(1):53-62. PubMed ID: 5279883
[No Abstract] [Full Text] [Related]
33. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I; Verrecchia F; Crenn V; Redini F; Trichet V
Cells; 2020 Apr; 9(4):. PubMed ID: 32326444
[TBL] [Abstract][Full Text] [Related]
34. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
35. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.
Lo WW; Wunder JS; Dickson BC; Campbell V; McGovern K; Alman BA; Andrulis IL
Cancer; 2014 Feb; 120(4):537-47. PubMed ID: 24151134
[TBL] [Abstract][Full Text] [Related]
36. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
37. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.
Bielack SS; Kempf-Bielack B; Heise U; Schwenzer D; Winkler K
J Clin Oncol; 1999 Apr; 17(4):1164. PubMed ID: 10561175
[TBL] [Abstract][Full Text] [Related]
38. Growth factors, their receptor expression and markers for proliferation of endothelial and neoplastic cells in human osteosarcoma.
Bianchi E; Artico M; Di Cristofano C; Leopizzi M; Taurone S; Pucci M; Gobbi P; Mignini F; Petrozza V; Pindinello I; Conconi MT; Della Rocca C
Int J Immunopathol Pharmacol; 2013; 26(3):621-32. PubMed ID: 24067459
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic approach of primary bone tumours by bisphosphonates.
Moriceau G; Ory B; Gobin B; Verrecchia F; Gouin F; Blanchard F; Redini F; Heymann D
Curr Pharm Des; 2010; 16(27):2981-7. PubMed ID: 20722622
[TBL] [Abstract][Full Text] [Related]
40. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
